Treatment strategies in controlling strongyloidiasis

Abstract

Strongyloidiasis is an intestinal parasite infection caused by Strongyloides stercoralis. Spontaneous cure cannot be expected due to the unique life cycle of the parasite, termed autoinfection. The disease occurs worldwide, but especially in tropical and subtropical regions. Serious clinical problems with complications and refractory strongyloidiasis are observed, especially in immunocompromised patients, such as those infected with human T cell leukaemia virus Type 1 (HTLV-1) or HIV, or corticosteroid-treated patients. Thiabendazole is effective against S. stercoralis infection; however, serious side effects have been reported. Recently, ivermectin, which has been introduced for the treatment of human onchocerciasis, has been reported to be effective against strongyloidiasis, without serious side effects. The interval of administration is important for treatment, because if autoinfective migrating larvae are not eradicated, S. stercoralis will resume its life cycle and multiply again. To evaluate the results of treatment of S. stercoralis, stool examinations and S. stercoralis-specific antibody titres should be examined for at least 1 or 2 years if possible. This article provides a review of treatments and methods of evaluation of patients infected with S. stercoralis.

In Vitro and in Silico Identification and Characterization of Thiabendazole as a Mechanism-Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions

“…The k inact value of 0.08 min Ϫ1 is relatively high, such that the resulting k inact /K I of 0.05 M/min is predictive of likely significant enzyme inactivation. In the treatment of strongyloidiasis in humans, the drug is given over 3 days at 25 mg/kg/day (Merck, 1999;Satoh and Kokaze, 2004), thus providing the time component during which CYP1A2 will progressively be The docking experiment was performed in GLUE as described under Materials and Methods. The color coding is the same as described for legend 7.…”

Strongyloides stercoralis: current perspectives

“…79,80 Patients with hyperinfection who have peripheral eosinophilia appear to have a better prognosis than patients without peripheral eosinophilia. 40 However, eosinophils are not specific to Strongyloides since any helminthic infection can …”

Advances in the Diagnosis of Human Strongyloidiasis

“…Whilst seroconversion does not always take place in patients with strongyloidiasis, serum levels tend to decrease after effective treatment [9,47,[76][77][78][79][80][81].…”